Propensity-based study of aminoglycoside nephrotoxicity in patients with severe sepsis or septic shock

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7468-7474

  Picard, W ^a,c   Bazin, F ^b   Clouzeau, B ^a   Bui, H N ^a   Soulat, M ^a   Guilhon, E ^a   Vargas, F ^a   Hilbert, G ^a   Bouchet, S ^a,b   Gruson, D ^a   Moore, N ^a,b   Boyer, A ^a,b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b INSERM U657   (France)

^c Service de Réanimation Polyvalente CH Pau   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CREATININE; GENTAMICIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; COHORT ANALYSIS; CREATININE CLEARANCE; FEMALE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROTOXICITY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; TREATMENT DURATION; AGED; BACTERIAL INFECTIONS; CHEMICALLY INDUCED; DRUG ADMINISTRATION; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PROPENSITY SCORE; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; SURVIVAL;

ACUTE KIDNEY INJURY; ADULT; AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; SURVIVAL ANALYSIS;

EID: 84912552006     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03750-14     Document Type: Article

References (40)

1. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. 2004. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 328:668. http://dx.doi.org/10 .1136/bmj.38028.520995.63.
2. Kumar A, Safdar N, Kethireddy S, Chateau D. 2010. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a metaanalytic/ meta-regression study. Crit. Care Med. 38:1651-1664. http://dx .doi.org/10.1097/CCM.0b013e3181e96b91.
3. Durante-Mangoni E, Grammatikos A, Utili R, Falagas ME. 2009. Do we still need the aminoglycosides? Int. J. Antimicrob. Agents 33:201-205. http://dx.doi.org/10.1016/j.ijantimicag.2008.09.001.
4. Leibovici L, Vidal L, Paul M. 2009. Aminoglycoside drugs in clinical practice: an evidence-based approach. J. Antimicrob. Chemother. 63: 246-251. http://dx.doi.org/10.1093/jac/dkn469.
5. Beardsley JR, Williamson JC, Johnson JW, Ohl CA, Karchmer TB, Bowton DL. 2006. Using local microbiologic data to develop institutionspecific guidelines for the treatment of hospital-acquired pneumonia. Chest 130:787-793. http://dx.doi.org/10.1378/chest.130.3.787.
6. Bhat S, Fujitani S, Potoski BA, Capitano B, Linden PK, Shutt K, Paterson DL. 2007. Pseudomonas aeruginosa infections in the intensive care unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved? Int. J. Antimicrob. Agents 30:458-462. http://dx.doi.org/10 .1016/j.ijantimicag.2007.05.022.
7. Marcus R, Paul M, Elphick H, Leibovici L. 2011. Clinical implications of beta-lactam-aminoglycoside synergism: systematic review of randomised trials. Int. J. Antimicrob. Agents 37:491-503. http://dx.doi.org/10.1016/j .ijantimicag.2010.11.029.
8. Slaughter RL, Cappelletty DM. 1998. Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug monitoring. PharmacoEconomics 14:385-394. http://dx.doi.org/10.2165/00019053 -199814040-00005.
9. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. 2007. Back to the future: using aminoglycosides again and how to dose them optimally. Clin. Infect. Dis. 45:753-760. http://dx.doi.org/10 .1086/520991.
10. Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. 2008. Suboptimal aminoglycoside dosing in critically ill patients. Ther. Drug Monit. 30:674-681. http://dx.doi.org/10.1097/FTD.0b013e31818b6b2f.
11. Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA. 2002. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med. 28:936-942. http://dx.doi.org/10 .1007/s00134-002-1313-7.
12. Fayed DF, Dahmash NS, al-Zeer AH, Shibl AM, Huraib SO, Abu-Aisha H. 1996. Efficacy and safety of once-daily amikacin in combination with ceftazidime in critically ill adults with severe gram-negative infections. J. Chemother. 8:457-464. http://dx.doi.org/10.1179/joc.1996.8.6.457.
13. Schentag JJ, Plaut ME, Cerra FB. 1981. Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients. Antimicrob. Agents Chemother. 19:859-866. http://dx.doi.org /10.1128/AAC.19.5.859.
14. French MA, Cerra FB, Plaut ME, Schentag JJ. 1981. Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients. Antimicrob. Agents Chemother. 19:147-152. http://dx .doi.org/10.1128/AAC.19.1.147.
15. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. 2004. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care 8:R204-R212. http://dx.doi.org/10.1186/cc2872.
16. Selby NM, Shaw S, Woodier N, Fluck RJ, Kolhe NV. 2009. Gentamicinassociated acute kidney injury. QJM 102:873-880. http://dx.doi.org/10 .1093/qjmed/hcp143.
17. Li SC, Ioannides-Demos LL, Spicer WJ, Berbatis C, Spelman DW, Tong N, McLean AJ. 1989. Prospective audit of aminoglycoside usage in a general hospital with assessments of clinical processes and adverse clinical outcomes. Med. J. Aust. 151:224-232.
18. Shrimpton SB, Milmoe M, Wilson AP, Felmingham D, Drayan S, Barrass C, Gruneberg RN, Ridgway GL. 1993. Audit of prescription and assay of aminoglycosides in a UK teaching hospital. J. Antimicrob. Chemother. 31:599-606. http://dx.doi.org/10.1093/jac/31.4.599.
19. Boyer A, Gruson D, Bouchet S, Clouzeau B, Hoang-Nam B, Vargas F, Gilles H, Molimard M, Rogues AM, Moore N. 2013. Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk. Drug Saf. 36:217-230. http://dx.doi.org/10.1007/s40264-013 -0031-0.
20. Taber SS, Mueller BA. 2006. Drug-associated renal dysfunction. Crit. Care Clin. 22:357-374, viii. http://dx.doi.org/10.1016/j.ccc.2006.02.003.
21. Ostermann M., Chang RW. 2007. Acute kidney injury in the intensive care unit according to RIFLE. Crit. Care Med. 35:1837-1843, 1852. http: //dx.doi.org/10.1097/01.CCM.0000277041.13090.0A.
22. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R. 2013. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit. Care Med. 41:580-637. http://dx .doi.org/10.1097/CCM.0b013e31827e83af.
23. American Thoracic Society. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcareassociated pneumonia. Am. J. Respir. Crit. Care Med. 171:388-416. http: //dx.doi.org/10.1164/rccm.200405-644ST.
24. Pannu N, Nadim MK. 2008. An overview of drug-induced acute kidney injury. Critical care medicine. 36:S216-223. http://dx.doi.org/10.1164 /rccm.200405-644ST.
25. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. 1984. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann. Intern. Med. 100:352-357. http://dx.doi.org/10.7326/0003-4819-100-3 -352.
26. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. 2006. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med. 34:1589-1596. http://dx.doi.org/10.1097/01.CCM.0000217961.75225.E9.
27. da Silva Winter J, Dos Santos RP, de Azambuja AZ, Cechinel AB, Goldani LZ. 2013. Microbiologic isolates and risk factors associated with antimicrobial resistance in patients admitted to the intensive care unit in a tertiary care hospital. Am. J. Infect. Control 41:846-848. http://dx.doi.org /10.1016/j.ajic.2012.11.010.
28. Fulnecky EJ, Wright D, Scheld WM, Kanawati L, Shoham S. 2005. Amikacin and colistin for treatment of Acinetobacter baumannii meningitis. J. Infect. 51:e249-e251. http://dx.doi.org/10.1016/j.jinf.2005.04.003.
29. Rocco M, Montini L, Alessandri E, Venditti M, Laderchi A, De Gennaro P, Raponi G, Vitale M, Pietropaoli P, Antonelli M. 2013. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit. Care 17:R174. http://dx.doi.org/10.1186 /cc12853.
30. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. 1999. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob. Agents Chemother. 43:1549-1555.
31. Ricci Z, Polito A, Polito A, Ronco C. 2011. The implications and management of septic acute kidney injury. Nat. Rev. Nephrol. 7:218-225. http: //dx.doi.org/10.1038/nrneph.2011.15.
32. Philipponnet C, Guerin C, Canet E, Robert R, Mariat C, Dijoud F, Azoulay E, Souweine B, Heng AE. 2013. Kidney biopsy in the critically ill patient, results of a multicentre retrospective case series. Minerva Anestesiol. 79:53-61.
33. Zager RA. 1992. Endotoxemia, renal hypoperfusion, and fever: interactive risk factors for aminoglycosideandsepsis-associated acute renal failure.Am.J. Kidney Dis. 20:223-230. http://dx.doi.org/10.1016/S0272-6386(12)80694-9.
34. Lipcsey M, Carlsson M, Larsson A, Algotsson L, Eriksson M, Lukinius A, Sjolin J. 2009. Effect of a single dose of tobramycin on systemic inflammatory response-induced acute kidney injury in a 6-hour porcine model. Crit. Care Med. 37:2782-2790. http://dx.doi.org/10.1097/CCM.0b013e3181a988f8.
35. Langenberg C, Gobe G, Hood S, May CN, Bellomo R. 2014. Renal histopathology during experimental septic acute kidney injury and recovery. Crit. Care Med. 42:e58-e67. http://dx.doi.org/10.1097/CCM .0b013e3182a639da.
36. Drusano GL, Louie A. 2011. Optimization of aminoglycoside therapy. Antimicrob. Agents Chemother. 55:2528-2531. http://dx.doi.org/10 .1128/AAC.01314-10.
37. Matthaiou DK, De Waele J, Dimopoulos G. 2014. What is new in the use of aminoglycosides in critically ill patients? Intensive Care Med. 40:1553-1555. http://dx.doi.org/10.1007/s00134-014-3376-7.
38. Bragadottir G, Redfors B, Ricksten SE. 2013. Assessing glomerular filtration rate (GFR) in critically ill patients with acute kidney injury - true GFR versus urinary creatinine clearance and estimating equations. Crit. Care 17:R108. http://dx.doi.org/10.1186/cc12777.
39. Kellum JA, Lameire N. 2013. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). Crit. Care 17:204. http: //dx.doi.org/10.1186/cc11454.
40. Braitman LE, Rosenbaum PR. 2002. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann. Intern. Med. 137: 693-695. http://dx.doi.org/10.7326/0003-4819-137-8-200210150-00015.